Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2018-11-09 Regulatory Filings
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience och Aptevo Therapeutics presenterar nya prekliniska data för ALG.APV-527 på Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Regulatory Filings Classification · 1% confidence The document is a press release dated November 9, 2018, announcing that Alligator Bioscience and Aptevo Therapeutics will present new preclinical data for their drug candidate ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting. It details the scientific findings (mechanism of action, tumor types targeted) and mentions future plans (CTA submission in 2019). This content is characteristic of an announcement regarding scientific progress or research findings, often released to investors and the public. It is not a formal regulatory filing (like 10-K or IR), a transcript (CT), or a formal earnings release (ER). Since it details scientific data presentation and research progress, it fits best under the general category of Investor Presentation (IP) or potentially Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on presenting scientific data at a conference, 'Investor Presentation' (IP) is the most appropriate fit, as these press releases often accompany or precede investor-focused presentations of data. It is not a formal presentation document itself, but an announcement about one, which often falls under IP or RNS. Since it is a detailed announcement about scientific data being presented, IP is chosen over the general RNS.
2018-11-09 Swedish
Alligator Bioscience erhåller mångmiljonintäkt - AbClon-partner utnyttjar option
Capital/Financing Update Classification · 1% confidence The document is a press release from Alligator Bioscience dated November 7, 2018, announcing that they will receive payments exceeding 30 million SEK because their partner, AbClon, had a third party (Henlius) exercise an option to expand regional rights to global rights for an antibody (AC101). This announcement details a significant financial event related to licensing agreements and partnership revenue realization. It is not a full annual report (10-K), an interim report (IR), an earnings release (ER) focusing on period performance, or a formal regulatory filing like a DEF 14A or DVA. Since it announces a specific financial transaction/update related to financing/licensing revenue, it best fits the Capital/Financing Update (CAP) category, as it details a major cash inflow resulting from a licensing deal structure. Given the context of a press release announcing a specific financial milestone from a partnership agreement, CAP is the most appropriate fit over the general RNS.
2018-11-07 Swedish
Alligator Bioscience to receive million-dollar payments - AbClon partner exercises option
Capital/Financing Update Classification · 1% confidence The document announces a specific corporate event: Alligator Bioscience receiving payments due to a partner (AbClon) exercising an option related to a licensing agreement with a third party (Henlius). This involves financing/revenue milestones triggered by a contractual event, which directly relates to the company's capital structure or fundraising activities, although it's triggered by a licensing deal milestone. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement regarding a financial transaction/milestone payment. This fits best under Capital/Financing Update (CAP) as it details incoming funds based on an agreement structure, or potentially Regulatory Filings (RNS) if it were a general disclosure. Given the specific nature of receiving milestone payments and option exercises, CAP is the most precise fit among the provided options, as it concerns the company's financial structure/funding events derived from partnerships. The document is short and is a direct announcement, not a report itself.
2018-11-07 English
Valberedning utsedd inför årsstämma 2019 i Alligator Bioscience AB
AGM Information Classification · 1% confidence The document is titled "Valberedning utsedd inför årsstämma 2019 i Alligator Bioscience AB" (Nomination Committee appointed ahead of the 2019 Annual General Meeting). It details the composition and mandate of the Nomination Committee responsible for preparing proposals for the upcoming AGM, including board members and remuneration. This content directly relates to the preparation and governance surrounding the Annual General Meeting (AGM). While it is an announcement about the AGM process, the specific focus on the Nomination Committee's composition and duties aligns most closely with the governance aspects leading up to the meeting, which is often covered under AGM-related materials or Governance Information (CGR). However, since the core subject is the appointment of the committee for the AGM, AGM-R (AGM Information) is the most specific fit, as these appointments are integral parts of the AGM process documentation.
2018-11-06 Swedish
Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB
Board/Management Information Classification · 1% confidence The document explicitly discusses the appointment of the Nomination Committee in preparation for the 'Annual General Meeting (AGM) on May 9, 2019'. It details the composition, rights, and tasks of this committee, which is directly related to the governance and proceedings of the AGM. This aligns perfectly with the definition of 'AGM Information' (Code: AGM-R), which covers presentations and materials shared during the AGM, including preparatory announcements like committee appointments.
2018-11-06 English
Alligator Bioscience utökar pipeline: Inleder preklinisk utveckling av läkemedelskandidaten ATOR-1144
Regulatory Filings Classification · 1% confidence The document is a press release dated October 30, 2018, announcing that Alligator Bioscience has initiated preclinical development for a new drug candidate, ATOR-1144. It details the scientific nature of the drug (bispecific antibody targeting CTLA-4 x GITR) and includes standard boilerplate information about the company and investor relations contacts. Crucially, the text ends with a statement indicating it is information the company is required to make public under EU market abuse regulation, which strongly suggests a regulatory disclosure. Since it is an announcement about a specific development milestone (preclinical entry) rather than a full financial report (10-K, IR), a dividend (DIV), or a management change (MANG), it fits best as a general regulatory announcement or a specific type of corporate update. Given the options, this type of specific corporate/pipeline update that is mandated for public disclosure often falls under the general 'Regulatory Filings' (RNS) category if a more specific code like 'CAP' (Capital/Financing) or 'LTR' (Legal) does not apply. It is not an Earnings Release (ER), Interim Report (IR), or a presentation (IP). It is a specific corporate action announcement, making RNS the most appropriate fallback for a non-standard, mandatory disclosure.
2018-10-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.